Latest Novakand Pharma News & Updates

See the latest news and media coverage for Novakand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novakand Pharma

Biopharmaceutical developer of biomarker-guided orphan drugs

novakand.com

Company type: Public company
Number of employees: 4–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Novakand Pharma

In short: Novakand Pharma shifted its strategy toward cancer orphan drugs and planned a new share issue following its delisting from Nasdaq.

Company announcements

August 28 Novakand Pharma

Novakand Pharma presents the half-year report for the first half of 2026

The company reports about Nasdaq delisting, new board and strategic shift towards cancer drugs at an operating loss of 6.3 million kronor.

July 16 Novakand Pharma

Novakand Pharma announces regarding management, website and extraordinary general meeting

Thomas Olin becomes acting CEO, Björn Petersson CFO, new website launched, and extraordinary general meeting in September with items about capital raising.

June 25 Novakand Pharma

Novakand Pharma shifts strategy to orphan drugs for cancer

Focus shifts from cardiovascular diseases to treatment-resistant ovarian cancer and leukemia, with support from new board and clinical data.

May 26 Novakand Pharma

Novakand Pharma announces AGM results on 25 May 2026

The meeting approved financial statements, decided to retain earnings, and elected new board members including Michael Zell as chairman.

Media coverage

June 23 Barron's

Novakand Pharma AB

Novakand Pharma AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate...

March 3 MFN.se

MFN.se > Novakand Pharma > Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Background Novakand Pharma AB (”Novakand” or the ”Company”) announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North...

February 24 The Pharma Letter

BRIEF—SVF Vaccines intended merger with Novakand will not be carried out

KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of...

February 24 FinanzNachrichten.de

The observation status for Novakand Pharma AB is updated

On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference to the Company's disclosure of its interim...

Never miss news about Novakand Pharma

Track Novakand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novakand Pharma competitors & trending companies

Browse news for competitors to Novakand Pharma and other trending companies.